Potential role for Interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection
Open Access
- 29 July 2010
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Hepatology
- Vol. 52 (4), 1216-1224
- https://doi.org/10.1002/hep.23850
Abstract
Polymorphisms in the IL28B (interleukin‐28B) gene region are important in predicting outcome following therapy for chronic hepatitis C virus (HCV) infection. We evaluated the role of IL28B in spontaneous and treatment‐induced clearance following recent HCV infection. The Australian Trial in Acute Hepatitis C (ATAHC) was a study of the natural history and treatment of recent HCV, as defined by positive anti‐HCV antibody, preceded by either acute clinical HCV infection within the prior 12 months or seroconversion within the prior 24 months. Factors associated with spontaneous and treatment‐induced HCV clearance, including variations in IL28B, were assessed. Among 163 participants, 132 were untreated (n = 52) or had persistent infection (infection duration ≥26 weeks) at treatment initiation (n = 80). Spontaneous clearance was observed in 23% (30 of 132 participants). In Cox proportional hazards analysis (without IL28B), HCV seroconversion illness with jaundice was the only factor predicting spontaneous clearance (adjusted hazards ratio = 2.86; 95% confidence interval = 1.24, 6.59; P = 0.014). Among participants with IL28B genotyping (n = 102 of 163 overall and 79 of 132 for the spontaneous clearance population), rs8099917 TT homozygosity (versus GT/GG) was the only factor independently predicting time to spontaneous clearance (adjusted hazard ratio = 3.78; 95% confidence interval = 1.04, 13.76; P = 0.044). Participants with seroconversion illness with jaundice were more frequently rs8099917 TT homozygotes than other (GG/GT) genotypes (32% versus 5%, P = 0.047). Among participants adherent to treatment and who had IL28B genotyping (n = 54), sustained virologic response was similar among TT homozygotes (18 of 29 participants, 62%) and those with GG/GT genotype (16 of 25, 64%, P = 0.884). Conclusion: During recent HCV infection, genetic variations in IL28B region were associated with spontaneous but not treatment‐induced clearance. Early therapeutic intervention could be recommended for individuals with unfavorable IL28B genotypes. (HEPATOLOGY 2010;)Keywords
This publication has 25 references indexed in Scilit:
- Spontaneous clearance and the beneficial impact of treatment on clearance during recent hepatitis C virus infectionJournal of Viral Hepatitis, 2010
- Effective Treatment of Injecting Drug Users With Recently Acquired Hepatitis C Virus InfectionGastroenterology, 2010
- Acute Hepatitis C Virus Infection in Young Adult Injection Drug Users: A Prospective Study of Incident Infection, Resolution, and ReinfectionThe Journal of Infectious Diseases, 2009
- Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistenceJCI Insight, 2009
- New insights into the immunopathogenesis of chronic hepatitis CAntiviral Research, 2009
- Immunological determinants of the outcomes from primary hepatitis C infectionCellular and Molecular Life Sciences, 2008
- Acute hepatitis C virus infection: A chronic problemHepatology, 2007
- Acute Hepatitis C in a Contemporary US Cohort: Modes of Acquisition and Factors Influencing Viral ClearanceThe Journal of Infectious Diseases, 2007
- Peginterferon Alfa-2b Therapy in Acute Hepatitis C: Impact of Onset of Therapy on Sustained Virologic ResponseGastroenterology, 2006
- Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studiesJournal of Viral Hepatitis, 2005